Ineffective therapy, underpowered studies, or merely too little, too late?: Risk factors and impact of maternal corticosteroid treatment on outcome in antibody-associated fetal heart block

Circulation

Volumn 124, Issue 18, 2011, Pages 1905-1907

  Pike, Jodi I ^a,b   Donofrio, Mary T ^a,b   Berul, Charles I ^a,b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; RO ANTIBODY;

ANTIBODY ASSOCIATED FETUS HEART BLOCK; ATRIOVENTRICULAR BLOCK; CORTICOSTEROID THERAPY; FETUS DISEASE; FETUS HEART; HUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIBODIES, ANTINUCLEAR; ATRIOVENTRICULAR BLOCK; FEMALE; FETAL DEATH; FETAL DISEASES; HEART BLOCK; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY;

EID: 80155142557     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.061267     Document Type: Review

References (20)

1. Hayashi N, Koshiba M, Nishimura K, Sugiyama D, Nakamura T, Morinobu S, Kawano S, Kumagai S. Prevalence of disease-specific antinuclear antibodies in general population: estimates from annual physical examinations of residents of a small town over a 5 year period. Mod Rheumatol. 2008;18:153-160.
2. Hornberger LK, Al Rajaa N. Spectrum of cardiac involvement in neonatal lupus. Scand J Immunol. 2010;72:189-197.
3. Jaeggi ET, Hamilton RM, Silverman ED, Zamora SA, Hornberger LK. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block: a single institution's experience of 30 years. J Am Coll Cardiol. 2002;39:130-137. (Pubitemid 34059872)
4. Llanos C, Izmirly PM, Katholi M, Clancy RM, Friedman DM, Kim MY, Buyon JP. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum. 2009;60: 3091-3097.
5. Cimaz R, Spence DL, Hornberger L, Silverman ED. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr. 2003;142: 678-683. (Pubitemid 36737172)
6. Costedoat-Chalumeau N, Amoura Z, Lupoglazoff JM, Huong DL, Denjoy I, Vauthier D, Sebbouth D, Fain O, Georgin-Lavialle S, Ghillani P, Musset L, Wechsler B, Duhaut P, Piette JC. Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. Arthritis Rheum. 2004;50:3187-3194. (Pubitemid 39371995)
7. Costedaut-Chalumeau N, Amoura Z, Villain E, Cohen L, Piette JC. Anti-SSA/Ro antibodies and the heart: more than complete congenital heart block? a review of electrocardiographic and myocardial abnormalities and of treatment options. Arthritis Res Ther. 2005;7:69-73. (Pubitemid 40439441)
8. Julkunen H, Eronen M. The rate of recurrence of isolated congenital heart block: A population based study. Arthritis Rheum. 2001;44:487-488.
9. Buyon JP, Hiebert R, Copel J, Craft J, Friedman D, Katholi M, Lee LA, Provost TT, Reichlin M, Rider L, Rupel A, Saleeb S, Weston WL, Skovron ML. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol. 1998;31:1658-1666. (Pubitemid 28273312)
10. Ho SY, Esscher E, Anderson RH, Michaëlsson M. Anatomy of congenital complete heart block and relation to maternal anti-Ro antibodies. Am J Cardiol. 1986;58:291-294. (Pubitemid 16052720)
11. Xiao GQ, Hu K, Boutjdir M. Direct inhibition of expressed cardiac L-and T-type calcium channels by IgG from mothers whose children have congenital heart block. Circulation. 2001;103:1599-1604. (Pubitemid 32226271)
12. Gordon P, Khamashta MA, Rosenthal E, Simpson JM, Sharland G, Brucato A, Franceschini F, De Bosschere K, Meheus L, Meroni PL, Hughes GR, Buyon J. Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. J Rheumatol. 2004;31:2480-2487. (Pubitemid 39603101)
13. Eliasson H, Sonesson SE, Sharland G, Granath F, Simpson JM, Carvalho JS, Jicinska H, Tomek V, Dangel J, Zielinsky P, Respondek-Liberska M, Freund MW, Mellander M, Bartrons J, Gardiner HM, for the Fetal Working Group of the European Association of Pediatric Cardiology. Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study of 175 patients. Circulation. 2011;124:1919-1926.
14. Izmirly PM, Saxena A, Kim MY, Wang D, Sahl SK, Llanos C, Friedman D, Buyon JP. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation. 2011;124:1927-1935.
15. Jaeggi ET, Fouron JC, Silverman ED, Ryan G, Smallhorn J, Hornberger KL. Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation. 2004;110:1542-1548. (Pubitemid 39297974)
16. Friedman DM, Kim MY, Copel JA, Llanos C, Davis C, Buyon JP. Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) study. Am J Cardiol. 2009;103:1102-1107.
17. Breur JM, Visser GH, Kruize AA, Stoutenbeek P, Meijboom EJ. Treatment of fetal heart block with maternal steroid therapy: case report and review of the literature. Ultrasound Obstet Gynecol. 2004;24: 467-472. (Pubitemid 39179486)
18. Donofrio MT, Gullquist SD, Mehta ID, Moskowitz WB. Congenital complete heart block: fetal management protocol, review of the literature, and report of the smallest successful pacemaker implantation. J Perinatol. 2004;24:112-117. (Pubitemid 38401177)
19. Hofstaetter C, Hansmann M, Eik-Nes SH, Huhta JC, Luther SL. A cardiovascular profile score in the surveillance of fetal hydrops. J Matern Fetal Neonatal Med. 2006;19:407-413. (Pubitemid 44272914)
20. Shem S. The House of God. Putnam Publishing Group, New York, NY. 1978.